HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Koichiro Nomata Selected Research

Neoplasms (Cancer)

4/2014Oncological outcomes of hormonal therapy with a gonadotropin-releasing hormone agonist combined with a steroidal or non-steroidal antiandrogen in patients with prostate cancer.
9/2012Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis.
6/2010Green tea polyphenol suppresses tumor invasion and angiogenesis in N-butyl-(-4-hydroxybutyl) nitrosamine-induced bladder cancer.
1/2009TFE3-renal carcinoma in an adult patient: a case with strong expression of phosphorylated hepatocyte growth factor (HGFR)/Met.
1/2005Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract.
11/2004The preventive effect of green tea on the gap junction intercellular communication in renal epithelial cells treated with a renal carcinogen.
3/2004Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival.
7/2002[Feasibility and change in the level of blood paclitaxel concentration after paclitaxel therapy for a hemodialysis patient with cisplatin resistant metastatic transitional cell cancer].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Koichiro Nomata Research Topics

Disease

8Neoplasms (Cancer)
04/2014 - 07/2002
4Urinary Bladder Neoplasms (Bladder Cancer)
01/2016 - 02/2006
4Transitional Cell Carcinoma
06/2006 - 03/2004
3Neoplasm Metastasis (Metastasis)
02/2013 - 11/2002
3Carcinoma (Carcinomatosis)
01/2009 - 10/2002
2Carcinoma in Situ
01/2016 - 06/2004
2Renal Cell Carcinoma (Grawitz Tumor)
02/2013 - 11/2002
2Lymphatic Metastasis
01/2005 - 03/2004
1Hot Flashes
04/2014
1Prostatic Neoplasms (Prostate Cancer)
04/2014
1Pain (Aches)
09/2012
1Leukopenia
09/2012
1Venous Thrombosis (Deep-Vein Thrombosis)
02/2012
1Overactive Urinary Bladder (Overactive Bladder)
01/2011
1Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
01/2011
1Azoospermia
07/2007
1Oligospermia (Oligozoospermia)
07/2007
1Urinary Bladder Neck Obstruction (Bladder Neck Obstruction)
06/2005
1Adenocarcinoma
11/2004
1Non-Muscle Invasive Bladder Neoplasms
10/2002
1Ureteral Obstruction
10/2002
1Male Infertility (Male Sterility)
03/2002

Drug/Important Bio-Agent (IBA)

4Cisplatin (Platino)FDA LinkGeneric
09/2012 - 07/2002
3Proteins (Proteins, Gene)FDA Link
01/2009 - 10/2002
3Connexin 43 (Connexin43)IBA
07/2007 - 10/2002
2Paclitaxel (Taxol)FDA LinkGeneric
09/2012 - 07/2002
2GemcitabineFDA Link
09/2012 - 02/2012
2TeaIBA
06/2010 - 11/2004
2Dinoprostone (PGE2)FDA Link
06/2006 - 01/2005
1Androgen Antagonists (Antiandrogens)IBA
04/2014
1Chlormadinone Acetate (Chlormadinone)IBA
04/2014
1Gonadotropin-Releasing Hormone (GnRH)FDA Link
04/2014
1bicalutamide (Casodex)FDA LinkGeneric
04/2014
1AndrogensIBA
04/2014
1InterferonsIBA
02/2013
1Analgesics (Analgesic Drugs)IBA
09/2012
1Colony-Stimulating Factors (Colony Stimulating Factor)IBA
09/2012
1Warfarin (Coumadin)FDA LinkGeneric
02/2012
1naftopidilIBA
01/2011
1PolyphenolsIBA
06/2010
1Hematoxylin (Haematoxylon)IBA
06/2010
1Guanosine Triphosphate (GTP)IBA
06/2010
1NitrosaminesIBA
06/2010
1Eosine Yellowish-(YS) (Eosin)IBA
06/2010
1von Willebrand FactorIBA
06/2010
1Anticarcinogenic AgentsIBA
06/2010
1Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
01/2009
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2009
1Proto-Oncogene Proteins c-metIBA
01/2009
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
02/2006
1Vascular Endothelial Growth Factor DIBA
02/2006
1Vascular Endothelial Growth FactorsIBA
02/2006
1Vascular Endothelial Growth Factor CIBA
02/2006
1ParaffinIBA
01/2005
1Formaldehyde (Formol)FDA Link
01/2005
1Cyclooxygenase 2 (Cyclooxygenase-2)IBA
01/2005
1Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
01/2005
1Mucin-1 (CA 15-3 Antigen)IBA
11/2004
1Keratin-7 (Cytokeratin 7)IBA
11/2004
1MucinsIBA
11/2004
1VimentinIBA
11/2004
1AntigensIBA
11/2004
1ChromograninsIBA
11/2004
1Keratin-19 (Keratin 19)IBA
11/2004
1Tissue Inhibitor of Metalloproteinase-2IBA
03/2004
1Matrix Metalloproteinases (MMPs)IBA
03/2004
1Tissue Inhibitor of MetalloproteinasesIBA
03/2004
1Tissue Inhibitor of Metalloproteinase-1IBA
03/2004
1Epirubicin (Ellence)FDA LinkGeneric
10/2002
1Fas Ligand Protein (Fas Ligand)IBA
03/2002

Therapy/Procedure

8Therapeutics
01/2016 - 07/2002
3Nephrectomy
02/2013 - 11/2002
1Intramuscular Injections
02/2013
1Aftercare (After-Treatment)
09/2012
1Radiotherapy
07/2007
1Drug Therapy (Chemotherapy)
07/2007
1Adjuvant Chemotherapy
10/2002
1Intravesical Administration
10/2002
1Renal Dialysis (Hemodialysis)
07/2002